Exelixis (EXEL) Q1 2026: Cash Up, Cabozantinib Momentum, and a Pipeline Push That Could Rewire the Landscape

Overview

Exelixis, Inc. (ticker: EXEL) reported its first-quarter 2026 results, highlighting a solid revenue base and a cash-rich balance sheet that the company intends to put to work. For the quarter, Exelixis posted total revenues of $610.8 million, with Cabozantinib U.S. net product revenues amounting to $555.0 million. On the earnings line, GAAP diluted earnings per share (EPS) came in at $0.79, while non-GAAP EPS stood at $0.87. The company did not publish a formal EPS consensus in its release, and there was no explicit revenue forecast beyond highlighting quarterly performance against internal milestones. In short, Exelixis reaffirmed its cash-generating core while teeing up a broader set of pipeline and strategic moves.

Key Takeaways

Revenue and EPS: Total revenue of $610.8 million; GAAP EPS of $0.79 and Non-GAAP EPS of $0.87 for Q1 2026.
Product momentum: The cabozantinib franchise continued to be the cash engine, delivering the lion’s share of US net product revenue.
No explicit earnings surprise: The release did not cite an EPS consensus or imply a formal surprise vs. street estimates in the provided text.
Capital return plan: Exelixis disclosed a stock repurchase program of up to $750 million through 2027, with a second $750 million program authorized by the board in May 2026, signaling a strong balance-sheet confidence and a willingness to return capital.
Pipeline push: The company laid out a robust R&D cadence around zanzalintinib, including milestones for multiple STELLAR programs, and highlighted a collaboration with Merck around LITESPARK-034 testing zanzalintinib in combination with WELIREG in advanced RCC.

Capital Allocation and Cash Strategy

The cash generation at Exelixis is paired with a plan to deploy capital for shareholder value. The company announced a stock repurchase program of up to $750 million by the end of 2027, and an additional $750 million authorization approved in May 2026. In practice, this posture provides a cushion against dilution and signals management’s confidence in the underlying cash flow and long-term value of the business. For investors, the question is whether this cadence of buybacks will outpace any near-term cadence of pipeline-related outlays and whether the repurchase activity will meaningfully move the stock in an environment where holding periods are being measured in quarters, not years.

Pipeline and R&D Trajectory

A central theme is Exelixis’s effort to diversify beyond cabozantinib. The company underscored progress toward zanzalintinib, noting acceptance of its first NDA for an initial indication in previously treated metastatic colorectal cancer and ongoing pivotal development across multiple STELLAR studies. Management also highlighted ongoing collaboration with Merck (LITESPARK-034) evaluating zanzalintinib in combination with WELIREG (belzutizumab) in advanced renal cell carcinoma, with Merck initiating the second Phase 3 trial under the collaboration. In addition, the company outlined a series of development milestones—STELLAR-303 and STELLAR-304 readouts, continued enrollment in STELLAR-311, initiation of STELLAR-316, and initiation of STELLAR-201 in recurrent meningioma—alongside new expansion activities (STELLAR-202 in lung cancer) and a Phase 1b/2 expansion in STELLAR-002 for combination trials with docetaxel in castration-resistant prostate cancer. Taken together, Exelixis is positioning zanzalintinib as a potential growth driver should these data milestones translate into meaningful clinical readouts and regulatory progress.

Implications for Exelixis and Sector Peers

The quarter reinforces the central market dynamic for oncology companies: solid revenue streams from established products can fund a higher-risk, higher-reward R&D agenda. For EXEL, the mix—strong cabozantinib revenues paired with a pipeline built around zanzalintinib—suggests a two-track strategy: maintain near-term cash flow while pursuing long-run growth through novel indications and combination therapies. If ongoing Phase 2/3 data or NDA milestones for zanzalintinib begin to deliver meaningful efficacy signals, the stock could re-rate on the probability of a broader franchise that complements cabozantinib's existing footprint.

For sector peers, the emphasis on strategic collaborations (e.g., with Merck) and the deployment of a sizable buyback alongside aggressive clinical milestones may become a proxy play: can a company sustain a high cadence of R&D while still returning capital? Investors will watch how Exelixis balances the cash outflows for development with the liquidity cushion that underpins the buyback program. The broader takeaway: a diversified pipeline plus disciplined capital allocation can support multiple levers of value creation, even in a sector where clinical outcomes drive the ultimate multiple.

Bottom Line

Exelixis delivered a convincing quarter in terms of revenue and EPS, anchored by cabozantinib’s ongoing momentum, and backed by a bold capitalization plan. The real test lies ahead: whether zanzalintinib can translate early-stage enthusiasm into durable revenue streams and whether the collaboration with Merck yields a data-driven path to new approvals. In the near term, EXEL trades on the interplay between quarterly results and long-run pipeline milestones, with EPS metrics and revenue trajectory serving as the common substrate for both risk assessments and valuation work. For investors tracking EXEL, the narrative remains: a proven cash generator guiding a portfolio of risky-but-promising oncology bets, with a buyback banner waving in the background.